I-ne Co., Ltd. (Headquarters: Chuo-ku, Osaka) has launched a new skincare brand 'REPROID' and will release the dry skin trouble treatment cream 'Medical Face Cream' (Sales name: Medi ICH Cream, Class 2 OTC drug) starting May 2026.
Product name: REPROID Medical Face Cream (Sales name: Medi ICH Cream, Class 2 OTC drug) Price: 4,950 yen (tax included) Release date / Distribution: Sequentially from May 18, 2026 [EC] Official online store, EC malls (Rakuten Ichiba, Amazon) [In-store] (Currently on sale) Some dispensing pharmacies
*According to our research (as of March 2026) / As an OTC drug with the same active ingredient combination sold in Japan
Development Background The spread of beauty treatments and the need for 'defensive' skincare
With beauty treatments such as peeling and lasers becoming more common, there is a growing demand for products that can appropriately care for skin troubles such as roughness, itching, and extreme dryness during downtime*.
The new skincare brand 'REPROID' was developed jointly with a long-established manufacturer founded in 1960, aiming to treat extreme dryness and skin troubles that cannot be fully addressed by regular skincare through three approaches: 'soothing, repairing, and moisturizing'.
*When you lack confidence in your skin's impression
Product Features [1] First in Japan*1! 'Dry skin treatment face cream' combining 5 active ingredients*2
In addition to 'Heparinoid 0.3%', which is at the same level as prescription drugs from dermatologists, it contains 'Diphenhydramine' to stop itching, 'Dipotassium Glycyrrhizate' to soothe inflammation, and 'Panthenol' and 'Tocopherol Acetate' to promote blood circulation and help tissue repair. This combination is a unique formulation not found in the existing medical skincare market.
*1 According to our research (as of March 2026) / Domestically released identical...
FACT BOX
- Source: PR TIMES
- Category: New Product